On 25 September 2026 the FDA recorded a supplement to new drug application 207924, for baricitinib, marketed as Olumiant.
The record does not state what the supplement covers. Supplements can range from manufacturing changes to labelling updates; without the labelling text, nothing can be said about a new indication or safety change.
Baricitinib is a JAK inhibitor used for rheumatoid arthritis, alopecia areata and, in some settings, COVID-19, and the class carries boxed warnings for serious infection, malignancy, major cardiovascular events and thrombosis. Those warnings remain the basis for prescribing decisions.
- No prescribing change follows from this filing; its content is not stated.
- Check the current label before acting on any reported change to baricitinib indications or warnings.
- Continue to screen for tuberculosis and hepatitis B before starting a JAK inhibitor.
- Weigh cardiovascular and thrombotic risk, especially in older patients and smokers, as the class warnings advise.
Why it matters
Any change to a JAK inhibitor label is worth tracking, but this record alone gives nothing to act on.
Don't overread it
A licence supplement is not a new indication, and the record does not say what changed.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for clinical pharmacology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free